- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06177613
Advantages of Early Intrauterine Transfer of "Blank" Culture Medium Prior to 1st or 2nd Transfer of Thawed Embryo(s). (TRABLAN)
Advantages of Early Intrauterine Transfer of "Blank" Culture Medium Prior to 1st or 2nd Transfer of Thawed Embryo(s). Randomized, Single-blind, Multicenter Controlled Trial.
Despite technical advances in Medically Assisted Reproduction (AMP), the success of fertility treatments is sometimes limited by embryo implantation failure. The coordinated development of the embryo and the uterine endometrium requires close communication between the maternal tissue and the embryo. In in vitro fertilization (IVF), embryo transfer generally takes place between the 2nd (D2) and the 6th (D6) day following oocyte fertilization. Recent studies have shown the advantages of sequential transfer (transfer of an embryo on D2/D3 followed by the transfer of another embryo on D5/D6), with higher implantation and clinical pregnancy rate, fewer miscarriages, more live births, and yet no increase in multiple pregnancies. However, the American Society for Reproductive Medicine recommendations continue to prioritize the transfer of a single embryo for all patients aged under 38. To improve pregnancy rates for patients having a single embryo transferred, the study investigators wish to carry out on "blank" transfer, based on the principle of sequential transfer. The study investigators hypothesize that a culture medium, placed in the uterus before the time of embryo transfer, will modify immune tolerance. The study will test whether transferring the same culture medium in an equivalent quantity as during the real transfer into the uterus 2/3 days before the embryo transfer will improve tolerance to this foreign medium and, therefore, embryo implantation. The aim of this study is thus to evaluate the impact of a "blank" transfer with culture medium alone, on the results of frozen embryo transfers (FET) from IVF.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Clamart, Frankrike
- Hôpital Antoine Béclère
-
Contamine-sur-Arve, Frankrike
- Centre Hospitalier Alpes Léman
-
Montpellier, Frankrike
- CHU Arnaud de Villeneuve
-
Montpellier, Frankrike
- Clinique Saint Roch
-
Nîmes, Frankrike, 30029
- CHU de Nîmes
-
Perpignan, Frankrike
- Clinique Saint-Pierre
-
-
-
-
-
Saint-Pierre, Gjenforening
- CHU de la Réunion
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Having had a first "fresh" or frozen embryo transfer, whatever the embryo's stage of development, transfer followed by pregnancy failure ;
- Frozen embryos must be at least D3 stage;
- The patient must have given their free and informed consent and signed the consent form
- The patient must be a member or beneficiary of a health insurance plan
Exclusion Criteria:
- The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study
- The patient is under safeguard of justice or state guardianship
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Med blank kultur
|
A maximum of 0.1 ml of gassed embryo culture medium preheated to 37°C is injected into the uterine cavity transcervically using an embryo transfer catheter placed just beyond the internal os, two to 3 days before transfer of the thawed embryo |
|
Sham-komparator: Uten blank kultur
|
An intermediate transfer step is added two or three days before the planned transfer of the frozen embryo but with an empty catheter. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinically progressive pregnancy rate between groups
Tidsramme: 12 weeks of amenorrhea
|
Measured on first-trimester ultrasound |
12 weeks of amenorrhea
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Occurrence of pregnancy between groups
Tidsramme: Day 14
|
Defined by a positive beta HCG test ≥ 100 IU/ml |
Day 14
|
|
Occurrence of a biochemical pregnancy between groups
Tidsramme: Day 14
|
Defined by a positive beta HCG test ≥ 10 IU/ml and < 100 IU/ml |
Day 14
|
|
Occurrence of a clinical pregnancy between groups
Tidsramme: 6 weeks of amenorrhea
|
Defined by a positive beta HCG test ≥ 100 IU/ml and presence of at least one gestational sac on dating ultrasound |
6 weeks of amenorrhea
|
|
Occurrence of an early miscarriage between groups
Tidsramme: 12 weeks of amenorrhea
|
Defined by the presence of a pregnancy defined by a positive beta HCG test ≥ 100 IU at D14 and the absence of an evolving clinical pregnancy at first-trimester ultrasound |
12 weeks of amenorrhea
|
|
Occurrence of live birth
Tidsramme: Upon giving birth (maximum month 9)
|
Yes/no |
Upon giving birth (maximum month 9)
|
|
Differential cost-result ratio
Tidsramme: End of study (Year 3)
|
Ratio of the cost differential and the number of additional live births (additional progressive clinical pregnancies) between the two strategies, to evaluate the cost per additional live birth. |
End of study (Year 3)
|
|
Total estimated expenditure for the two care strategies compared (budget impact analysis) over a one-year time horizon.
Tidsramme: End of study (Year 3)
|
Calculated at national level (implementation of the system and consumption of care) |
End of study (Year 3)
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Nathalie Rougier, CHU de Nimes
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- PHRC-I/2022/NR-01
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .